Emerging agents that target signaling pathways in cancer stem cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playing critical roles in CSC progression, such as the Wnt, Hedgehog, Notch, Hippo, and autophagy signaling pathways. Additionally, targeting the ferroptosis signaling pathway was recently shown to specifically kill CSCs. Therefore, targeting these pathways may suppress CSC progression. The structure of small-molecule drugs shows a good spatial dispersion, and its chemical properties determine its good druggability and pharmacokinetic properties. These characteristics make small-molecule drugs show a great advantage in drug development, which is increasingly popular in the market. Thus, in this review, we will summarize the current researches on the small-molecule compounds suppressing CSC progression, including inhibitors of Wnt, Notch, Hedgehog, and autophagy pathways, and activators of Hippo and ferroptosis pathways. These small-molecule compounds emphasize CSC importance in tumor progression and propose a new strategy to treat cancer in clinic via targeting CSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192 · cited 1×
“Sulfasalazine can also inhibit the Xc − system, thereby inhibiting the progression of CSCs overexpression of CD44 in gastrointestinal cancer [141].”
BackgroundResolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis
Shah, R., Shchepinov, M. S., & Pratt, D. A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00589 · Cited by 782
Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561
Regulation of lipid peroxidation and ferroptosis in diverse species
Conrad, M., Kagan, V. E., Bayir, H., Pagnussat, G. C., Head, B., Traber, M. G., & Stockwell, B. R. (2018) · Genes & Development · doi:10.1101/gad.314674.118 · Cited by 544
Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells
Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., & Brady, N. R. (2015) · Oncoscience · doi:10.18632/oncoscience.160 · Cited by 524
Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05220-6 · Cited by 437
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004766 · Cited by 435
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y., Conner, M., Hidalgo, B., Alvarez, R. D., Landen, C. N., Straughn, J. M., & Buchsbaum, D. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.005 · Cited by 161 · cited 1×
“Niclosamide has been shown to selectively target ovarian CSCs [36].”
Background
Cited by
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Furthermore, CSCs exhibit critical features of embryonic stem cells (ESCs) in terms of transcriptional factor expression (SOX2, OCT4, NANOG, MYC, KLF4, SALL4, and FOXM1) and signaling pathways (like Wnt/β-catenin, Hedgehog, Hippo, Notch, and TGF-β) [99–101].”
BackgroundThe Role of Iron in Cancer Progression
Guo, Q., Li, L., Hou, S., Yuan, Z., Li, C., Zhang, W., Zheng, L., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.778492 · Cited by 150
Self-citationTanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis
Ni, H., Ruan, G., Sun, C., Yang, X., Miao, Z., Li, J., Chen, Y., Qin, H., Liu, Y., Zheng, L., et al. (2022) · Environmental Toxicology · doi:10.1002/tox.23388 · Cited by 72
Self-citationTargeted Cancer Stem Cell Therapeutics: An Update
Fatima, N., Umar, M., Ambreen, S., Shaququzzaman, M., Alam, M. M., & Ali, R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266275014240110071351 · Cited by 6
Metadata
- Authors
- Yang, Y., Li, X., Wang, T., Guo, Q., Xi, T., & Zheng, L.
- Venue
- Journal of Hematology & Oncology
- Published
- 2020-05-26
- Volume
- 13
- Issue
- 1
- Pages
- 60-60
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W3031460986
- Cited by
- 176
- References
- 12
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging agents that target signaling pathways in cancer stem cells. https://app.cochat.ai/papers/10.1186/s13045-020-00901-6
- The paper
- Yang, Y., Li, X., Wang, T., Guo, Q., Xi, T., & Zheng, L. (2020). Emerging agents that target signaling pathways in cancer stem cells. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-00901-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.